JOHNSON & JOHNSON is 5.1x more valuable than Bristol-Myers Squibb Company by market capitalization ($574.10 B vs $113.54 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | BMY | JNJ |
|---|---|---|
| Market cap | $113.54 B | $574.10 B |
| US-listed rank | #132 | #20 |
| Revenue (latest FY) | $48.19B | $94.19B |
| Net income (latest FY) | $7.05B | $26.80B |
| Net margin | 14.6% | 28.5% |
| P/E (trailing FY) | 16.1 | 21.4 |
| SEC filings | 1,000 | 984 |
JOHNSON & JOHNSON is 5.1x more valuable than Bristol-Myers Squibb Company by market capitalization ($574.10 B vs $113.54 B).
In their latest fiscal years, Bristol-Myers Squibb Company reported $48.19B in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Bristol-Myers Squibb Company and JOHNSON & JOHNSON, or browse the full rankings.